[Clinical and electroencephalographic study of a new antidepressive agent, mono-methyl-amino-propyl-dibenzo-bicyclo-octadine hydrochloride (Ciba 34, 276 Ba)].
A clinical trial on fifty patients studied a new compound with a quadricyclic structure, Ciba 34.276-Ba or Maprotiline in any category of depression. The product was found to have notable antidepressive properties, capable to act on the melancholic depressions of the manic depressive psychosis and of involutive melancholia. The best results were noted in the neurotic and reactive depressions perhaps because a tranquilizing activity marked in the majority of the cases. The clinical tolerance was found good and the side effects which reminded of those caused by derivates of Imipramine, remained moderate while the biological tolerance was perfect. The modifications of the electroencephalogram were of two types, one of them suggesting thymoanaleptic activity, the other suggesting rather a sedative activity.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000873:Anthracenes / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy; D003863:Depression / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008376:Maprotiline / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001523:Mental Disorders / Q000188:drug therapy*
D000873:Anthracenes; D008376:Maprotiline
Etude clinique et électro-encéphalographique d'un nouvel agent antidépresseur, le chlorhydrate de mono- méthyl-amino-propyl-dibenzo-bicyclo-octadiène (Ciba 34.276 Ba)